{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971810",
  "id": "02971810",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0953",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1vmvqs891ts.pdf",
  "summary": "**Capital Raising Announcement Summary:**  \n\n- **Structure:**  \n  - Placement (A$25 million) + Share Purchase Plan (SPP) (A$2.5 million, with potential oversubscription up to A$10 million total).  \n  - Placement price: A$0.23/share (19.3% discount to last close, 22.8% discount to 5-day VWAP).  \n\n- **Key Dates:**  \n  - **SPP Record Date:** 22 July 2025.  \n  - **Unconditional Placement Settlement:** 28 July 2025.  \n  - **SPP Open/Close:** 1\u201322 August 2025.  \n  - **AGM (for conditional approvals):** 27 August 2025.  \n\n- **Use of Funds:**  \n  - Accelerate clinical trials (ACCENT, AMPLICITY, kRAS/ovarian cancer) and manufacturing.  \n  - Extends cash runway into 2027 (total funding post-raise: A$42.7 million, including existing cash/R&D refunds).  \n\n- **Material Updates:**  \n  - Top-line ACCENT trial data expected late July/August 2025.  \n  - Firm commitments for A$2.5 million SPP shortfall.  \n\n*Omitted: Director participation details, boilerplate, non-material operational updates.*",
  "usage": {
    "prompt_tokens": 2948,
    "completion_tokens": 289,
    "total_tokens": 3237,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T23:57:54.140713"
}